Essential fatty acid supplementation in tardive dyskinesia. 1986

A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen

Preclinical and clinical observations suggest that enhancement of prostaglandin activity inhibits catecholamine release and may have antidyskinetic effects. A double-blind therapeutic trial with prostaglandin precursor essential fatty acids was conducted in 16 patients with tardive dyskinesia. No beneficial effects were seen.

UI MeSH Term Description Entries
D008042 Linolenic Acids Eighteen-carbon essential fatty acids that contain three double bonds.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017965 gamma-Linolenic Acid An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) Gamolenic Acid,gamma-Linolenic Acid, Ammonium Salt,gamma-Linolenic Acid, Cerium Salt,gamma-Linolenic Acid, Indium Salt,gamma-Linolenic Acid, Lithium Salt,gamma-Linolenic Acid, Potassium Salt,gamma-Linolenic Acid, Sodium Salt,gamma-Linolenic Acid, Zinc Salt,Acid, Gamolenic,Acid, gamma-Linolenic,gamma Linolenic Acid,gamma Linolenic Acid, Ammonium Salt,gamma Linolenic Acid, Cerium Salt,gamma Linolenic Acid, Indium Salt,gamma Linolenic Acid, Lithium Salt,gamma Linolenic Acid, Potassium Salt,gamma Linolenic Acid, Sodium Salt,gamma Linolenic Acid, Zinc Salt

Related Publications

A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
March 1989, Psychiatry research,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
April 2006, International review of psychiatry (Abingdon, England),
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
July 1996, Schizophrenia research,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
August 1993, Lancet (London, England),
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
December 1983, Biological psychiatry,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
August 1996, Alimentary pharmacology & therapeutics,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
January 1979, Prostaglandins and medicine,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
January 1984, Psychopharmacology bulletin,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
January 2003, Ryoikibetsu shokogun shirizu,
A Wolkin, and B Jordan, and E Peselow, and M Rubinstein, and J Rotrosen
January 1980, British medical journal,
Copied contents to your clipboard!